Associations of MALAT1 rs619586/rs3200401 and ANRIL rs10965215/rs10738605 polymorphisms with type 2 diabetes and diabetic nephropathy risk in an Egyptian population.
Diabetic nephropathy (DN) is a serious microvascular complication of type 2 diabetes mellitus (T2DM).Single-nucleotide polymorphisms (SNPs) in long non-coding RNAs MALAT1 and ANRIL may influence their expression and function, potentially affecting T2DM and DN risk.
To investigate the association of MALAT1 SNPs rs619586 and rs3200401 and ANRIL SNPs rs10965215 and rs10738605 with T2DM and/or DN susceptibility and clinical correlates in an Egyptian population.
This case-control study included 64 T2DM patients, 75 DN patients, and 70 healthy controls from Fayoum University Hospital. Genomic DNA was extracted from peripheral blood, and SNP genotyping was performed using TaqMan real-time PCR. All analyses were adjusted for age and sex. The study had 80% power to detect associations based on expected differences in allele frequencies.
MALAT1 rs619586 GG genotype and G allele were associated with reduced T2DM risk (adjusted odds ratio (AOR) 0.31, P = 0.004 and DN risk (AOR 0.32, P = 0.003). Conversely, MALAT1 rs3200401 CT/TT genotypes increased T2DM risk (AOR 4.69, P<0.001) and DN risk (AOR 5.41, P<0.001). ANRIL rs10965215 GA/AA and rs10738605 CG genotypes were also associated with increased T2DM and DN risk versus controls. Notably, none of the SNPs were associated with DN progression among T2DM patients. This study is the first report of ANRIL SNPs in DN susceptibility.
MALAT1 rs619586 appears protective against T2DM and DN, while MALAT1 rs3200401 and ANRIL rs10965215/rs10738605 increase susceptibility. These SNPs may serve as early risk markers pending validation in larger cohorts.
To investigate the association of MALAT1 SNPs rs619586 and rs3200401 and ANRIL SNPs rs10965215 and rs10738605 with T2DM and/or DN susceptibility and clinical correlates in an Egyptian population.
This case-control study included 64 T2DM patients, 75 DN patients, and 70 healthy controls from Fayoum University Hospital. Genomic DNA was extracted from peripheral blood, and SNP genotyping was performed using TaqMan real-time PCR. All analyses were adjusted for age and sex. The study had 80% power to detect associations based on expected differences in allele frequencies.
MALAT1 rs619586 GG genotype and G allele were associated with reduced T2DM risk (adjusted odds ratio (AOR) 0.31, P = 0.004 and DN risk (AOR 0.32, P = 0.003). Conversely, MALAT1 rs3200401 CT/TT genotypes increased T2DM risk (AOR 4.69, P<0.001) and DN risk (AOR 5.41, P<0.001). ANRIL rs10965215 GA/AA and rs10738605 CG genotypes were also associated with increased T2DM and DN risk versus controls. Notably, none of the SNPs were associated with DN progression among T2DM patients. This study is the first report of ANRIL SNPs in DN susceptibility.
MALAT1 rs619586 appears protective against T2DM and DN, while MALAT1 rs3200401 and ANRIL rs10965215/rs10738605 increase susceptibility. These SNPs may serve as early risk markers pending validation in larger cohorts.
Authors
Ali Ali, Abdealeem Abdealeem, Shaker Shaker, Algammal Algammal, Hemeda Hemeda, Ali Ali, Makloph Makloph, Mohamed Mohamed, Elebiary Elebiary, Saleh Saleh, Kamal Kamal, Mohamed Mohamed, El-Masry El-Masry
View on Pubmed